We take our seats at the table. Brass arrives with coffee—hot, black, served in mismatched mugs.
“The good china.” Brass sets the mugs down with a thud.
Fuse snorts, then winces and presses a hand to his side. “Don’t make me laugh. Everything hurts.”
Torque leans back in his chair, spinning a pen through his fingers. “Then don’t listen to me. I’m hilarious.”
“Debatable.” Whisper doesn’t look up from his screen.
“Lies. I’m at least forty percent comedy gold.”
“Twenty. On a good day.” Fuse grins.
I wrap my hands around the warmth and prepare to tell the story of the worst ten days of my life.
---
The debriefing takes three hours.
We walk them through everything—the extraction from DC, the safe houses, the near-misses. The Philadelphia hotel and my disastrous log on that nearly got us killed. Diego explains the tactical decisions—when to run, when to hide, when to fight. I explain the discoveries—the paper trail that led us from Vanguard Defense to Stratton Financial to a decommissioned research facility in West Virginia.
At the back of the room, Thorne listens without speaking. The knife turns slowly in his hands. His gaze misses nothing.
The team listens. Ghost is motionless at the head of the table, his eyes tracking between us. Brass takes notes on a tablet, his stylus moving in quick, efficient strokes. Whisper’s fingers never stop—he’s pulling up corroborating data in real time.
Fuse leans against the table throughout, shifting his weight periodically. The injury is clearly bothering him, but he refuses to sit. Refuses to show weakness. I understand that instinct. I’ve been living it for ten days.
Torque paces. Short, restless circuits around the perimeter of the room. The pilot who can’t stay grounded.
“The Stratton connection is solid.” I walk them through the financial architecture. “Julianna Stratton—CEO of Stratton Financial—signed contracts with at least three shell companies that trace back to Phoenix operations. Echo Logistics was the smoking gun. The scope of services specified ‘secure transportand cold storage for biological assets, Class 4.’ That’s hazmat protocol. Pathogens. Experimental compounds. Something requiring specialized containment.”
“And the destination?” Ghost interrupts for the first time in twenty minutes.
“A facility in Terra Alta, West Virginia.” Diego’s voice is flat with the memory. “Officially decommissioned. Unofficially, very much operational. Industrial refrigeration. Research infrastructure. Filing cabinets full of clinical trial data.”
“Most of them died. Neural hemorrhaging. Cognitive collapse. Organ failure. The notes described the failures as ‘conversion errors.’”
“Conversion, to what?” Brass’s stylus stops moving.
“We don’t know.” The admission is frustrating. “The technical language was dense—synaptic modification, neural pathway restructuring. I’d need a PhD in advanced biochemistry to even begin to untangle it. It’s beyond anything I’ve ever seen in a courtroom.”
“Wait,” Fuse says, leaning forward. “You connected it to ML-273?” He looks at Ghost. “We really should pull the other women in on this. Talia was tracking Meridian Pharmaceuticals burying data about 73 deaths. There has to be a connection. It’s too many coincidences.”
At the back wall, Thorne’s knife stops turning. He’s looking at me now. Something flickering in his expression.
“Some subjects survived,” Diego adds. “The records showed successful ‘conversions’ with sustained cognitive function. Whatever Phoenix is trying to do to human neurology, it’s getting better at it. The early trials had a ninety-plus percent mortality rate. The recent ones are closer to sixty percent.”
“Still catastrophic,” Ghost observes.
“Still progress. From Phoenix’s perspective.” Diego’s jaw tightens. “It’s iterating. Learning. Refining the process toward something it considers acceptable.”
Whisper’s voice cuts in from his workstation. “Cross-referencing ML-273 with existing intelligence. Limited matches. The compound appears in shipping manifests from Meridian Pharmaceuticals—a subsidiary of Northridge Defense Solutions, which is a subsidiary of Vanguard, which connects to the Nexus structure at three different nodes.” His fingers pause. “Unofficial classification doesn’t exist. The compound isn’t in any medical database, any research registry, any patent filing. On paper, it doesn’t exist.”
“Because it’s not meant to be found.” I lean forward. “Phoenix has been running parallel operations. One public—legitimate pharmaceutical research. One buried so deep that even the people involved don’t know what they’re part of.”
“Compartmentalization.” Ghost nods. “Classic intelligence structure. Each node only knows what it needs to function.”
“Exactly. And the Terra Alta facility connected to something larger.” I pull up the next slide. “We found shipping manifests, supply chain documentation. Everything pointed to a central hub in Nevada. A facility powered by?—”
